ReviewRheumatology (Oxford, England)2015
Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis.
Review in Rheumatology (Oxford, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The 2024 British Society for Rheumatology guideline for management of systemic sclerosis.Rheumatology (Oxford, England) · 2024Guideline
- Digital ulcer debridement in systemic sclerosis: a systematic literature review.Clinical rheumatology · 2020Pooled it
- Behaviour change interventions for the management of Raynaud's phenomenon: a systematic literature review.BMJ open · 2018Pooled it
- The effect of silver fibre gloves on Raynaud's phenomenon in patients with systemic sclerosis: a double-blind randomized crossover trial.Rheumatology (Oxford, England) · 2023Trial
- A pilot clinical trial with losartan in Myhre syndrome.American journal of medical genetics. Part A · 2021Trial
- Riociguat for the Treatment of Raynaud's Phenomenon: A Single-Dose, Double-Blind, Randomized, Placebo-Controlled Cross-Over Pilot Study (DIGIT).Clinical drug investigation · 2018Trial
- Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study.Arthritis & rheumatology (Hoboken, N.J.) · 2017Trial
- Effectiveness and Impact on Quality of Life of a Hand Rehabilitation Program in Longstanding Systemic Sclerosis: A Prospective, Non-Randomized, Controlled Pilot Study.Journal of clinical medicine · 2026Article
- Article
- Cold responses and hormonal echoes: a comprehensive view of Raynaud's vascular dysfunction.Inflammopharmacology · 2025Review
- Association Between Risk of Relapse and Type of Surgical Procedure for Raynaud's Disease.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- [Systemic sclerosis].Dermatologie (Heidelberg, Germany) · 2024Review
- Real life use of prostacyclin analog (iloprost), a multi-centric survey data from the Scleroderma study group Emilia Romagna (Sclero-RER) and review of the literature.Acta bio-medica : Atenei Parmensis · 2023Review
- State-of-the-art evidence in the treatment of systemic sclerosis.Nature reviews. Rheumatology · 2023Review
- Effects of Long-Term Intervention with Losartan, Aspirin and Atorvastatin on Vascular Remodeling in Juvenile Spontaneously Hypertensive Rats.Molecules (Basel, Switzerland) · 2023Article
- Management of systemic sclerosis: British Society for Rheumatology guideline scope.Rheumatology advances in practice · 2023Review
- Practical management of Raynaud's phenomenon - a primer for practicing physicians.Current opinion in rheumatology · 2022Review
- Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review.Clinical reviews in allergy & immunology · 2022Review
- Umbilical Cord Mesenchymal Stem Cells for Inhibiting the Fibrosis and Autoimmune Development in HOCl-Induced Systemic Scleroderma Mouse Model.International journal of stem cells · 2021Article
- Chilblain-like acral lesions in long COVID-19: management and implications for understanding microangiopathy.The Lancet. Infectious diseases · 2021Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveDigital vasculopathy (comprising RP, digital ulceration and critical digital ischaemia) is responsible for much of the pain and disability experienced by patients with SSc. However, there is a limited evidence base to guide clinicians in the management of SSc-related digital vasculopathy. Our aim was to produce recommendations that would be helpful for clinicians, especially for those managing patients outside specialist centres.
methodsThe UK Scleroderma Study Group set up several working groups to develop a number of consensus best practice pathways for the management of SSc-specific complications, including digital vasculopathy.
resultsThis overview presents the background and best practice consensus pathways for SSc-related RP, digital ulceration and critical ischaemia. Examples of drug therapies, including doses, are suggested in order to inform prescribing practice.
conclusionA number of treatment algorithms are provided that are intended to provide the clinician with accessible reference tools for use in daily management.
Indexed as
Identifiers
26116156What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.